|
Friday 22nd June 2012 |
Text too small? |
Fruit grower and coolstore and packhouse operator Seeka Kiwifruit Industries has reassured the market that no antibiotic tainted fruit entered the market.
In a trial update release on the pan-industry fight against the vine bacterial disease Pseudomona Syringae pv actinidiae, Seeka said it has been involved in approved trials testing the use of antibiotics as a defence.
The trials used streptomycin and oxytectracyclin and “were carried out under strict control processes following careful planning,” said Seeka chief executive Michael Franks, following recent media reports about antibiotic use in the kiwifruit industry.
There was never any intention to harvest fruit for consumption, all fruit was destroyed, he said.
One trial that commenced without the orchard specific approval by the Agricultural Compounds and Veterinary Medicines had been brought to ACVM’s attention by Seeka, Franks said.
Findings from these Seeka trials have been presented to the industry at its recent technical forums in the scientific advance for a cure for Psa-V.
Franks said regular monitoring across the industry is key to ensuring no antibiotic residue on any fruit.
Seeka's shares were unchanged at $1.76 today, and have surged 79 percent this year.
New Zealand's kiwifruit industry came under pressure after the Psa-V bacteria was discovered in 2010, infecting more than 40 percent of the nation's kiwifruit hectares.
BusinessDesk.co.nz
No comments yet
NZK Market Update - Earnings Guidance Upgrade
MEL - Meridian Energy monthly operating report for March 2026
April 17th Morning Report
CCC - ESQUIRES IRELAND RECOGNISED AS THE BEST IN IRISH AWARDS
FBU - Fletcher Building Quarterly Volume Report for Q3 FY26
April 16th Morning Report
SCT - 2026 Half Year Announcement
Devon Funds Morning Note - 14 April 2026
BNP Paribas accredited as Derivatives Market Maker
GXH - Response to media report